AGEN 1884

Drug Profile

AGEN 1884

Alternative Names: AGEN-1884

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Recepta biopharma
  • Class Antineoplastics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Cervical cancer
  • Phase I Cancer

Most Recent Events

  • 04 Jun 2018 Interim efficacy and adverse events data from a phase I/II trial in advanced refractory cancer presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018) (NCT03495882) (ACTRN12618000003279)
  • 01 Jun 2018 Adverse events data from a phase I trial in advanced and refractory Cancers presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO- 2018)
  • 16 Mar 2018 Agenus has issued and pending patents for Retrocyte Display™ technology platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top